This study is testing **NEO100**, a type of medicine made from plants, for people with a serious brain tumor called **glioma**. Gliomas can be tough to treat, and many people don’t survive long after being diagnosed. This study is testing if NEO100, which is given through the nose, can help patients with a specific gene change called an **IDH1 mutation**. The trial has two phases: Phase 1 to find the safest dose and Phase 2a to see how well it works. During the study, participants will take NEO100 four times a day in 28-day cycles. The trial will continue until the disease gets worse, the patient chooses to stop, or if they pass away.

• The study will last for multiple 28-day treatment cycles, as long as the patient tolerates it.
• Participants will need to self-administer the medication four times a day.
• Patients must have a specific gene mutation and meet other health criteria to join.